H. Thioflavin S
III. RESULTS
The Morris water maze (MWM) test was used to assess the effect of tBCCAO on learning memory in the AD mice.
The TG mice showed no improvement in latency in the MWM test over time after exposure to ischemia, whereas the WT mice showed decreased latency as the trial proceeded, irrespective of exposure to ischemia (Fig. 1A).
In addition, in the ischemia group, TG mice differed significantly from WT mice in terms of the time spent in the platform zone after removal of the platform (P = 0.0123;
Fig. 1B). These results suggest that ischemia had a greater effect on learning memory in TG than in WT mice. To measure the willingness to explore the new environment, the behavior spontaneous alternation behaviors were measured using Y maze (Fig. 1C). However, there was no statistical difference in Y maze alteration tests (Fig. 1D).
11
Figure 1. Effect of tBCCAO on memory as measured by the Morris water maze test and spontaneous alternation test in the Y maze. A. The escape latency of all trials, performed over 5 days, was significantly different between the ischemia TG group vs. ischemia WT (**P = 0.0039, *P = 0.0215 vs. Ischemia WT). B. The platform zone-crossing time was recorded during a trial with the platform removed.
Ischemia TG mice spent a significantly shorter amount of time in the platform zone than did Ischemia WT mice (*P =
12
0.0123 vs. Ischemia WT). C. Y Maze. D. There were no significant changes between WT groups and TG groups.
13
B. Neuronal cell death
Staining of cresyl violet and caspase-3 was performed to confirm neuronal cell death due to ischemia. Neuronal cell death shown by cresyl violet staining was greater in the ischemic TG group compared to ischemic WT group (P
= 0.0135) (Fig. 2A-B). Apoptosis stained by the caspase-3 did not show a significant difference between ischemic TG and ischemic WT groups (Fig. 2C). In addition, apoptosis was greater in the ischemia TG group than in the ischemia WT group, although the results of the caspase-3-positive cell count confirmed only an increasing tendency in the ischemia TG group (Fig. 2D). This finding reveals that a greater extent of necrosis and apoptosis was induced in ischemia TG mice and that these mice are more vulnerable to ischemia.
14
Figure 2. Effect of tBCCAO on neuronal cell death.
A. Cresyl violet staining of ischemic WT and TG mouse brains. In non-ischemic status, neuronal cells in the hippocampus looks smaller in TG group compared to WT group. Magnification, 100×. B. Cell count of cresyl violet-positive neuronal cells in hippocampal CA1 between ischemia WT and TG groups with cerebral ischemia. TG mice showed significantly more neuronal cell death than WT mice. Data are presented as the mean ± standard error of the mean. *P = 0.0135 vs. ischemia WT. C. Cleaved caspase-3 immunoreactivity was increased in the
15
hippocampal CA3 region in the ischemia TG group. D. Cell count of the 3,3′-diaminobenzidine (DAB)-positive cleaved caspase-3-positive cells in the hippocampal CA3 region between the WT and TG groups with cerebral ischemia. There were no significant differences in the number of these cells across ischemia groups.
16
C. Changes in Alzheimer’s pathology 1. Amyloid plaques
The thioflavin S-positive signal was evaluated in the cortex, hippocampus, and amygdala region. Amyloid plaques were not obviously observed in 14-month-old TG mice with or without cerebral ischemia (Fig. 3A). However, the thioflavin S-positive signal reflected the extracellular accumulation of amyloid aggregates in the amygdala of 18-month-old mice. (Fig. 3B).
17
Figure 3. Amyloid plaques’ thioflavin S expression in TG. A.
Amyloid plaques were not seen in 14-month-old TG mice.
B. Amyloid plaques were observed in the amygdala of 18-month-old TG mice. Magnification, 100×.
18
2. Amyloid precursor protein
The APP (Y188) signal was evaluated in the cortex, amygdala, and hippocampal CA1 regions. Positive signals were obtained in both TG mice but not observed in both WT mice. In the ischemia group in particular, atrophy was observed in the ischemic lesion (Fig. 4A-C). In the ischemia TG group, the intensity of Y188 staining tended to be reduced, but the number of Y188-positive cells in hippocampal CA1 was not significantly different between the control and ischemia groups (Fig. 4D). Double-staining for Y188 and NeuN confirmed that the Y188 signal was derived from neuronal amyloid (Fig. 4E).
19
20
Figure 4. Amyloid precursor Y188 expression. A-C. The amyloid precursor Y188 was expressed in TG mouse brains.
A. Cortex B. Amygdala C. Hippocampal CA1. D. There were no significant differences in the number of Y188-positive cells between control and ischemia TG groups’ hippocampal CA1. E. Merged images of Y188 and NeuN immunostaining confirms that Y188 staining reflects neuronal amyloid.
Magnification, 400×.
21
3. Tau protein
Staining with AT8 allowed the observation of tau protein.
Tau-positive signals were evaluated in the cortex and hippocampus. Positive cells increased in the ischemia WT group compared with the control WT group. The ischemia TG group also showed an increase in positive cells compared with the control group (Fig. 5A-B). The density of control/ischemia TG was measured, and the density of ischemia TG was found to be significantly increased (P = 0.0271) (Fig. 5C). These results indicate that ischemia caused hyperphosphorylation of tau leading to activation of glia cells, resulting in the staining of microglia and astrocytes to confirm glial changes.
22
Figure 5. Tau protein AT8 expression. A. Tau AT8 expression was increased in the hippocampal CA1 region of both TG mouse brains. B. Although tau AT8 expression was increased in the cortex in ischemic WT and TG mouse brains, this increased expression appears to be markedly greater in ischemia TG mice. C. Quantitative analysis of AT8 density in hippocampal CA1 confirmed that ischemia TG was significantly increased compared to control TG (P
= 0.0271). Magnification, 400×.
23
D. Glial changes
Immunohistochemistry experiments were conducted to investigate differences in neuropathological changes. Iba-1 expression in WT control and TG hippocampi were not significantly different between WT and TG group with and without cerebral ischemia, respectively. Nevertheless, the density of Iba-1 positive cells in mice with ischemia was significantly greater than in those without. WT mice exposed to ischemia demonstrated activation of microglia in the hippocampus while microglia were activated in the cortex as well as in the hippocampus of TG mice exposed to ischemia. Iba-1 expression density was quantified to compare Iba-1 expression in each group. The staining density for Iba-1 was significantly increased in both WT and TG mice after ischemia, as compared to that in control WT and TG mice. However, the amount did not differ between TG and WT mice exposed to ischemia (Fig. 6A-B). In the hippocampi of control WT and TG mice, normal astrocyte morphology was observed. In contrast, in WT mice exposed to ischemia, we observed astrogliosis in a region showing signs of cell death. We also observed a cavitation phenomenon in astrocyte-rich regions also showing signs of cell death in TG mice. The GFAP intensity results showed a significant difference between WT and TG groups for brain ischemia (P = 0.0231). Thus, mice exposed to ischemia were more vulnerable to
24
neuropathologic changes than were control mice, and TG mice were more vulnerable than WT mice (Fig. 6C-D).
25
Figure 6. Immunohistochemistry of hippocampal lesions. A.
Iba-1 expression was increased in the hippocampal CA1 region in the ischemic brains of both TG and WT groups after tBCCAO, suggesting increased microglial activation. B.
Iba-1 density was increased in the ischemia TG group compared to the ischemia WT group. However, there were no significant differences in the number of these cells across ischemia groups. C. GFAP expression of the hippocampal CA1 region in ischemic brain. D. Quantitative analysis of GFAP intensity confirmed that ischemia TG was significantly increased compared to ischemia WT. Data are
26
presented as the mean ± standard error of the mean. *P = 0.0231 vs. ischemia WT. Magnification, 400×.
27
IV. DISCUSSION
In this study, we investigated whether AD is particularly vulnerable to brain ischemia by using 3xTG-AD mice triple-transgenic for the APPSwe, tauP301L, and PS1M148V mutations (Sterniczuk, Antle et al. 2010). A significant cognitive decline was observed in the aged mice of the ischemic TG group when we tested their cognitive abilities using the MWM test after inducing cerebral ischemia. Furthermore, observation of the hippocampal CA1 region indicated that cell death was significantly increased in the TG mice as compared to their WT counterparts, indicating that the aged 3xTG-AD mouse is more vulnerable to cerebral ischemia. However, the characteristic AD pathologies did not show such differences.
It has been reported that cerebral hypoperfusion, an early characteristic of the AD brain, is associated with degenerative processes and cognitive decline. This study explored such potential mechanistic associations and studied the relationship between changes in amyloid precursor protein and Tau protein expression and neuropathology in the brains of 3xTG-AD mice. We generated neuropathological changes by inducing transient brain ischemia, which led to cognitive decline and increased levels of neuronal cell death, microglia, and astrocytes in mouse brains of the ischemia TG group. In addition,
28
morphological evidence of cellular atrophy was observed in the ischemia TG group compared to the control TG group.
Neuron cells were observed by merging of the double staining for amyloid precursor protein Y188, which proved that amyloid precursor protein Y188 is a neuronal amyloid.
Tau protein expression was observed in cells that were also identified as microglia. However, when amyloid beta was observed in the control / ischemia TG group, amyloid beta was not observed. Amyloid beta was observed, however, in 18-month-old TG positive controls.
Cerebral ischemia induces oxidative stress and inflammation in the brain, resulting in the breakdown of the blood–brain barrier (BBB). Consequently, microglia and astrocytes are activated and cause neuronal damage (Kahlson and Colodner 2016). Neuronal cell death occurs in the hippocampal CA1 region, which is vulnerable to ischemia. In addition, cerebral ischemia causes a decrease in CBF, resulting in impaired memory function and exacerbation of dementia. Amyloid beta precursor protein, amyloidogenic fragments, tau-like pathology, and other AD factors can be induced at the site of injury in brain ischemia (Kalaria 2000). Neurodegenerative diseases are observed as signs of cerebrovascular disease. Thus, according to our findings, cognitive impairment in AD is associated with cerebral ischemia and subsequent neuronal pathological changes.
29
In AD, the characteristic neurological changes displayed are often accompanied by additional vascular pathology and features of other neurodegenerative diseases (Kelly, He et al. 2017). According to clinical studies, cerebral vascular occlusion contributes to the pathogenesis of AD, and cerebrovascular disease in AD is more detrimental than cerebral vascular disease in the elderly (Kisler, Nelson et al. 2017). Ischemic stroke has recently been implicated as a factor in the deterioration of AD (Lee, Im et al. 2011).
The cognitive impairment resulting from the combination of AD and ischemic stroke is exacerbated compared to ischemic stroke-related or AD-only injury (Santos, Snyder et al. 2017). The complex relationship between AD and ischemic stroke includes cerebral hypoperfusion, energy deficiency, inflammation, dysfunction of capillaries, immune wasting, oxidative stress, and the accumulation of key proteins, including amyloid beta and Tau protein (Pendlebury 2012, Dong, Maniar et al. 2018).
Tauopathies, aggregations of Tau protein, are characterized by a fibrous inclusion found in neurons and glial cells. Activated microglia and astrocytes and increased levels of proinflammatory molecules are also pathological features of brain regions affected by Tau pathology (Leyns and Holtzman 2017).The occurrence of tauopathy, a major pathologic feature, appears to play a role in nerve inflammation and in aggravation of tau pathology and neurodegeneration (Qiu, Ng et al. 2016). In addition to toxic
30
protein aggregates, activated astrocytes and macrophages, as well as elevated inflammatory marker levels, are other pathological features characteristic of tauopathies (Kovacs 2015). Chronic glial activation may promote the formation of tangles and the reduction of connective compliance, leading to neurodegenerative diseases (Wyss-Coray and Mucke 2002, Ransohoff 2016).
Therefore, our results show that as tau-positive cells increase, astrocytes significantly increase, and tauopathy is affected by astrocytes (Verkhratsky, Olabarria et al.
2010), which is consequently associated with gliosis and neuroinflammation.
Taken together, the results of this study show that ischemia contributes to the cognitive dysfunction of AD and AD mice, who are more vulnerable to ischemic injury, such as apoptosis, necrosis, and neuronal cell death, and exacerbates cognitive deficits associated with this condition.
31
V. REFERENCES
1. Cechetti, F., A. S. Pagnussat, P. V. Worm, V. R. Elsner, J. Ben, M. S. da Costa, R. Mestriner, S. N. Weis and C.
A. Netto (2012). "Chronic brain hypoperfusion causes early glial activation and neuronal death, and subsequent long-term memory impairment." Brain Res Bull 87(1):
109-116.
2. De Silva, T. M. and A. A. Miller (2016). "Cerebral Small Vessel Disease: Targeting Oxidative Stress as a Novel Therapeutic Strategy?" Front Pharmacol 7: 61.
3. Delacourte, A., J. P. David, N. Sergeant, L. Buee, A.
Wattez, P. Vermersch, F. Ghozali, C. Fallet-Bianco, F.
Pasquier, F. Lebert, H. Petit and C. Di Menza (1999).
"The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease."
Neurology 52(6): 1158-1165.
4. Dong, S., S. Maniar, M. D. Manole and D. Sun (2018).
"Cerebral Hypoperfusion and Other Shared Brain Pathologies in Ischemic Stroke and Alzheimer's Disease." Transl Stroke Res 9(3): 238-250.
5. Fan, Y. L., J. Q. Wan, Z. W. Zhou, L. Chen, Y. Wang, Q.
Yao and J. Y. Jiang (2014). "Neurocognitive improvement after carotid artery stenting in patients with chronic internal carotid artery occlusion: a prospective, controlled, single-center study." Vasc Endovascular Surg 48(4): 305-310.
32
6. Ferrer, I., I. Lopez-Gonzalez, M. Carmona, L. Arregui, E. Dalfo, B. Torrejon-Escribano, R. Diehl and G. G.
Kovacs (2014). "Glial and neuronal tau pathology in tauopathies: characterization of disease-specific phenotypes and tau pathology progression." J Neuropathol Exp Neurol 73(1): 81-97.
7. Gorelick, P. B., A. Scuteri, S. E. Black, C. Decarli, S. M.
Greenberg, C. Iadecola, L. J. Launer, S. Laurent, O. L.
Lopez, D. Nyenhuis, R. C. Petersen, J. A. Schneider, C.
Tzourio, D. K. Arnett, D. A. Bennett, H. C. Chui, R. T.
Higashida, R. Lindquist, P. M. Nilsson, G. C. Roman, F.
W. Sellke and S. Seshadri (2011). "Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association." Stroke 42(9): 2672-2713.
8. Hardy, J. and D. J. Selkoe (2002). "The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics." Science 297(5580): 353-356.
9. Jo, W. K., A. C. Law and S. K. Chung (2014). "The neglected co-star in the dementia drama: the putative roles of astrocytes in the pathogeneses of major neurocognitive disorders." Mol Psychiatry 19(2): 159-167.
10. Kahlson, M. A. and K. J. Colodner (2016). "Glial Tau Pathology in Tauopathies: Functional Consequences."
33
Journal of experimental neuroscience 9(Suppl 2): 43-50.
11. Kalaria, R. N. (2000). "The role of cerebral ischemia in Alzheimer's disease." Neurobiol Aging 21(2): 321-330.
12. Kelly, S. C., B. He, S. E. Perez, S. D. Ginsberg, E. J.
Mufson and S. E. Counts (2017). "Locus coeruleus cellular and molecular pathology during the progression of Alzheimer’s disease." Acta Neuropathol Commun 5.
13. Kisler, K., A. R. Nelson, A. Montagne and B. V.
Zlokovic (2017). "Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease." Nat Rev Neurosci 18(7): 419-434.
14. Kovacs, G. G. (2015). "Invited review:
Neuropathology of tauopathies: principles and practice."
Neuropathol Appl Neurobiol 41(1): 3-23.
15. Lee, J. S., D. S. Im, Y. S. An, J. M. Hong, B. J. Gwag and I. S. Joo (2011). "Chronic cerebral hypoperfusion in a mouse model of Alzheimer's disease: an additional contributing factor of cognitive impairment." Neurosci Lett 489(2): 84-88.
16. Leyns, C. E. G. and D. M. Holtzman (2017). "Glial contributions to neurodegeneration in tauopathies." Mol Neurodegener 12(1): 50.
17. Lull, M. E. and M. L. Block (2010). "Microglial activation and chronic neurodegeneration."
Neurotherapeutics 7(4): 354-365.
34
18. Montagne, A., D. A. Nation, J. Pa, M. D. Sweeney, A.
W. Toga and B. V. Zlokovic (2016). "Brain imaging of neurovascular dysfunction in Alzheimer's disease." Acta Neuropathol 131(5): 687-707.
19. Moolman, D. L., O. V. Vitolo, J. P. Vonsattel and M. L.
Shelanski (2004). "Dendrite and dendritic spine alterations in Alzheimer models." J Neurocytol 33(3):
377-387.
20. Pendlebury, S. T. (2012). "Dementia in patients hospitalized with stroke: rates, time course, and clinico-pathologic factors." Int J Stroke 7(7): 570-581.
21. Qiu, L., G. Ng, E. K. Tan, P. Liao, N. Kandiah and L.
Zeng (2016). "Chronic cerebral hypoperfusion enhances Tau hyperphosphorylation and reduces autophagy in Alzheimer's disease mice." Sci Rep 6: 23964.
22. Ransohoff, R. M. (2016). "How neuroinflammation contributes to neurodegeneration." Science 353(6301):
777-783.
23. Santos, C. Y., P. J. Snyder, W. C. Wu, M. Zhang, A.
Echeverria and J. Alber (2017). "Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis." Alzheimers Dement (Amst) 7:
69-87.
24. Song, B., Q. Ao, Y. Niu, Q. Shen, H. Zuo, X. Zhang and Y. Gong (2013). "Amyloid beta-peptide worsens cognitive impairment following cerebral
ischemia-35
reperfusion injury." Neural Regen Res 8(26): 2449-2457.
25. Sterniczuk, R., M. C. Antle, F. M. Laferla and R. H.
Dyck (2010). "Characterization of the 3xTg-AD mouse model of Alzheimer's disease: part 2. Behavioral and cognitive changes." Brain Res 1348: 149-155.
26. Swaab, D. F., M. A. Hofman, P. J. Lucassen, A. Salehi and H. B. Uylings (1994). "Neuronal atrophy, not cell death, is the main hallmark of Alzheimer's disease."
Neurobiol Aging 15(3): 369-371; discussion 379-380.
27. Verkhratsky, A., M. Olabarria, H. N. Noristani, C. Y.
Yeh and J. J. Rodriguez (2010). "Astrocytes in Alzheimer's disease." Neurotherapeutics 7(4): 399-412.
28. Wyss-Coray, T. and L. Mucke (2002). "Inflammation in neurodegenerative disease--a double-edged sword." Neuron 35(3): 419-432.
29. Xu, X., B. Zhang, K. Lu, J. Deng, F. Zhao, B. Q. Zhao and Y. Zhao (2016). "Prevention of Hippocampal Neuronal Damage and Cognitive Function Deficits in Vascular Dementia by Dextromethorphan." Mol Neurobiol 53(5): 3494-3502.
36